Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
Nathan M Denlinger, Narendranath Epperla, Basem M William Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center (OSUCCC-James), The Ohio State University, Columbus, OH, USA Abstract: Marginal zone lymphomas (MZLs) consist of a diverse family of malignancies, which ar...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-03-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/management-of-relapsedrefractory-marginal-zone-lymphoma-focus-on-ibrut-peer-reviewed-article-CMAR |
| _version_ | 1818854359636639744 |
|---|---|
| author | Denlinger NM Epperla N William BM |
| author_facet | Denlinger NM Epperla N William BM |
| author_sort | Denlinger NM |
| collection | DOAJ |
| description | Nathan M Denlinger, Narendranath Epperla, Basem M William Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center (OSUCCC-James), The Ohio State University, Columbus, OH, USA Abstract: Marginal zone lymphomas (MZLs) consist of a diverse family of malignancies, which are derived from B-cells. The disease subtypes are recognized extranodal, nodal, and splenic MZLs. The disease characteristics, clinical course, and treatment vary considerably based on the site of involvement. In 2017, the US Food and Drug Administration approved ibrutinib, a first in class Bruton’s tyrosine kinase inhibitor that revolutionized the care of chronic lymphocytic leukemia patients; for, the treatment of relapsed/refractory MZL based on pivotal open-label Phase II trial demonstrated an overall response rate of 48%, with a complete response rate of 3%, median progression-free survival of 14.2 months, and median overall survival not yet reached at a median follow-up of 19.4 months. In this review, we aim to summarize the current conundrums in the management of MZL and the evolving role of ibrutinib in the treatment of MZL. Keywords: non-Hodgkin’s lymphoma, marginal zone, ibrutinib |
| first_indexed | 2024-12-19T07:51:28Z |
| format | Article |
| id | doaj.art-2d843e12a67a413ca5234018da35ec67 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-19T07:51:28Z |
| publishDate | 2018-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-2d843e12a67a413ca5234018da35ec672022-12-21T20:30:08ZengDove Medical PressCancer Management and Research1179-13222018-03-01Volume 1061562437441Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinibDenlinger NMEpperla NWilliam BMNathan M Denlinger, Narendranath Epperla, Basem M William Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center (OSUCCC-James), The Ohio State University, Columbus, OH, USA Abstract: Marginal zone lymphomas (MZLs) consist of a diverse family of malignancies, which are derived from B-cells. The disease subtypes are recognized extranodal, nodal, and splenic MZLs. The disease characteristics, clinical course, and treatment vary considerably based on the site of involvement. In 2017, the US Food and Drug Administration approved ibrutinib, a first in class Bruton’s tyrosine kinase inhibitor that revolutionized the care of chronic lymphocytic leukemia patients; for, the treatment of relapsed/refractory MZL based on pivotal open-label Phase II trial demonstrated an overall response rate of 48%, with a complete response rate of 3%, median progression-free survival of 14.2 months, and median overall survival not yet reached at a median follow-up of 19.4 months. In this review, we aim to summarize the current conundrums in the management of MZL and the evolving role of ibrutinib in the treatment of MZL. Keywords: non-Hodgkin’s lymphoma, marginal zone, ibrutinibhttps://www.dovepress.com/management-of-relapsedrefractory-marginal-zone-lymphoma-focus-on-ibrut-peer-reviewed-article-CMARNon-Hodgkin’s Lymphomamarginal zoneibrutinib |
| spellingShingle | Denlinger NM Epperla N William BM Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib Cancer Management and Research Non-Hodgkin’s Lymphoma marginal zone ibrutinib |
| title | Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib |
| title_full | Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib |
| title_fullStr | Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib |
| title_full_unstemmed | Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib |
| title_short | Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib |
| title_sort | management of relapsed refractory marginal zone lymphoma focus on ibrutinib |
| topic | Non-Hodgkin’s Lymphoma marginal zone ibrutinib |
| url | https://www.dovepress.com/management-of-relapsedrefractory-marginal-zone-lymphoma-focus-on-ibrut-peer-reviewed-article-CMAR |
| work_keys_str_mv | AT denlingernm managementofrelapsedrefractorymarginalzonelymphomafocusonibrutinib AT epperlan managementofrelapsedrefractorymarginalzonelymphomafocusonibrutinib AT williambm managementofrelapsedrefractorymarginalzonelymphomafocusonibrutinib |